European Journal of Pediatrics

, 169:245

Long-term treatment with recombinant insulin-like growth factor 1 (IGF-1) in a child with IGF-1 gene mutation

  • Daniela Concolino
  • Gianluca Muzzi
  • Simona Sestito
  • Giovanna Vega
  • Giuseppe Bonapace
  • Pietro Strisciuglio
Short Report

DOI: 10.1007/s00431-009-1004-2

Cite this article as:
Concolino, D., Muzzi, G., Sestito, S. et al. Eur J Pediatr (2010) 169: 245. doi:10.1007/s00431-009-1004-2
  • 113 Downloads

Abstract

We assessed the efficacy and safety of recombinant human insulin-like growth factor 1 (IGF-1) therapy over a period of 7.5 years in a child with severe IGF-1 deficiency. Recombinant human IGF-1 was administered subcutaneously in doses between 40 and 80 μg/kg once daily. Height velocity increased from 2 cm/year on average at baseline to 7.9 cm/year during the first year of treatment. In the following years, growth velocity was less but satisfactory during treatment, but decreased when therapy was stopped.

Keywords

rhIGF-1 therapy IGF-1 gene mutation 

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Daniela Concolino
    • 1
  • Gianluca Muzzi
    • 1
  • Simona Sestito
    • 1
  • Giovanna Vega
    • 1
  • Giuseppe Bonapace
    • 1
  • Pietro Strisciuglio
    • 1
  1. 1.Department of PediatricsUniversity “Magna Graecia” of CatanzaroCatanzaroItaly
  2. 2.Department of PediatricsUniversity “Federico II”NaplesItaly

Personalised recommendations